March 12, 2012 08:10 ET

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Makers Continue to Capitalize on Expiring Patents

NEW YORK, NY--(Marketwire - Mar 12, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at to have free access to these research reports.

As patents for billion dollar drugs continue to expire, many companies in the Generic Drug industry have been posting stellar quarterly and full-year reports. Many companies saw a strong finish to 2011, and 2012 could be poised to deliver similar results. Get your free reports on Mylan Inc. and Watson Pharmaceuticals Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Two companies that ended 2011 on a high note were Mylan Inc. and Watson Pharmaceuticals Inc. Mylan stated that adjusted diluted earnings per share for the three months ended December 31st, 2011 came in at $0.53, a jump of 18% when compared year-over-year. Total revenues for the quarter were also up. Mylan Inc. report is accessible for free by registering today at

Similarly, Watson also performed well, with fourth quarter revenues up 62% year-over-year and non-GAAP earnings soaring by 90% over the same comparable period. Watson Pharmaceuticals Inc. report is accessible for free by registering today at

Although some companies have encountered FDA hurdles as of late, successful companies have been releasing generic alternatives to big name drugs. Mylan newly announced, through its subsidiary Mylan Pharmaceuticals, that it has released the first product equivalent to Lexapro®, a Forest Laboratories product that had approximate 2011 sales of $2.9 billion.

The two Drugs - Generic stocks research reports are available for free by signing up now on


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information